References

J
Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian multicenter study. The Universitaires Cliniques St-Luc (UCL) collaborative group. Kidney Int. 1998;53(4):1022-1025.
Olysio [package insert]. 2017.
Jezequel C, Bardou-Jacquet E, Desille Y, et al. Survival of patients infected by chronic hepatitis C and F0F1 fibrosis at baseline after a 15 year follow-up [P0709]. J Hepatol. 2015;62(Suppl 2):S589.
Jhaveri R, Hashem M, El-Kamary SS, et al. Hepatitis C virus (HCV) vertical transmission in 12-month-old infants born to HCV-infected women and assessment of maternal risk factors. Open Forum Infect Dis. 2015;2(2):ofv089.
Jhaveri R. Diagnosis and management of hepatitis C virus-infected children. Pediatr Infect Dis J. 2011;30(11):983-985.
Jiang Y, Nwankwo C. Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drug in the United States: a mathematical model using data from the C-EDGE CO-STAR study. Presented at the Liver Meeting 2017; October 20–24, 2017; Washington, DC.
Jin F, Matthews GV, Grulich AE. Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review. Sex Health. 2017;14(1):28-41.
Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int. 1994;46(6):1700-1704.
Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 1995;40(1):17-25.
Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343(18):1290-1297.
Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993;328(7):465-470.
Jonas MM, Squires RH, Rhee S, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study. Hepatology. 2019:[Epub ahead of print]. doi:10.1002/hep.30840.
Jonas MM, Lon HK, Rhee S, et al. Pharmacokinetics of glecaprevir/pibrentasvir in children with chronic HCV infection: interim analysis of part 2 of the DORA study [abstract 1551]. The Liver Meeting. Boston. 2019.
Jonas MM, Romero R, Sokal EM, et al. Safety and efficacy of sofosbuvir/velpatasvir in pediatric patients 6 to <18 years old with chronic hepatitis C infection [abstract 748]. The Liver Meeting. 2019.
Jonas MM, Squires RH, Rhee S. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in pediatric patients with genotypes 1-6 chronic HCV infection: part 1 of the Dora study [abstract 2379]. The Liver Meeting. 2018.
Jonas MM, Romero R, Sokal EM, et al. Safety and efficacy of sofosbuvir/velpatasvir in pediatric patients 6 to <18 years old with chronic hepatitis C infection [abstract 748]. The Liver Meeting. 2019.
Jonas MM, Rhee S, Kelly DA, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study. Hepatology. 2021;74(1):19-27. doi:10.1002/hep.31841.
Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79(1):1-10.
Jones CM, Logan J, Gladden RM, Bohm MK. Vital Signs: Demographic and substance use trends among heroin users - United States, 2002-2013. MMWR Morb Mortal Wkly Rep. 2015;64(26):719-725.
Jones JM, Kracalik I, Levi ME, et al. Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020. MMWR Recomm Rep. 2020;69(4):1-16. doi:10.15585/mmwr.rr6904a1.
Top